cyrilzakka/clinical-trials huggingface dataset:
SARS-CoV-2/COVID-19 Infection Among Health Care Workers

The present study finds opportunities and justifications, taking into consideration that the nature of professional practice in health needs scientific evidence resulting from systematic and systemic studies to strengthen the basis for the decisions made to have an impact on various levels, from the patient to health management itself. In addition, Cabo Verdean authorities may benefit from new evidence obtained by this study. It intends, in a growing number of health professionals exposed or infected with SARS-CoV-2, in the different health structures of the country, to contribute to substantiate a better perception of the problem and the required solutions. Therefore, assessing the potential risk factors for SARS-CoV-2 infection among healthcare workers will be essential to characterize virus transmission, preventing future infections in them and providing the associated healthcare. Due to the advances and important changes described, questions arise that guide this research and allow us to identify the problem.

The problem is stated in the following starting questions:

What conditions and factors are associated with infection and non-infection by SARS-CoV-2 among health professionals working in the three hospitals on the islands of Santiago and São Vicente? Which are they (gender, age group, profession, type of contact, etc.)? Where do the infected HCW typically work (sector)? When and how did the infection occur? What is the prevalence of SARS-CoV-2 antibody in professionals with confirmed SARS-CoV-2 infection and in HCW that thought they were not infected by SARS-CoV-2? How long do anti-SARS-CoV-2 antibodies last? What is the impact of infection on unplanned absenteeism? Which symptoms and complaints (if any) persists after SARS-CoV-2 infection?

Eligibility Criteria:
Inclusion Criteria:

* Being a healthcare professional working in one of the hospitals where the study will take place
* Be aged ≥18 years;
* Cases: SARS-CoV-2 infection confirmed by PCR test and/or Rapid Antigen Test;
* Control: No evidence and/or record of past infection with SARS-CoV-2.

Exclusion Criteria:

* Case: Confirmation of diagnosis test for SARS-CoV-2 without indication of specimen collection date.
* Control: Suspected SARS-CoV-2 infection.
The Professional Values and Ethical Sensitivities During the COVID-19 Pandemic

This study was conducted to examine the professional values and ethical sensitivities of senior nursing students in distance education during the COVID-19 pandemic. During the COVID-19 process, senior nursing students continue their education with distance education practices. The sample consisted of 302 senior nursing students.


Eligibility Criteria:
Inclusion Criteria:

* being over the age of 18
* being a fourth level student
* agreed to participate in the research

Exclusion Criteria:

* being diagnosed with a neuropsychiatric disease
Acceleration Time Assessment for Prediction of Critical Limb Ischemia

Critical Limb Ischaemia (CLI), the final stage of arterial disease, is a therapeutic emergency whose prognosis depends largely on the time taken to diagnose it. The growing prevalence of this condition and the associated healthcare costs make it an important public health objective. Diagnostic criteria for Critical Limb Ischaemia differ between learned societies and countries.

Its diagnosis is most frequently based on the combination of a clinical criterion (ischaemic decubitus pain and/or necrotic wounds, with a time to onset \> 2 weeks) and a haemodynamic criterion (ankle systolic pressure (ASP) \< 50mmHg or toe systolic pressure (TSP) \< 30 mmHg or transcutaneous oxygen pressure (TCPO2) \< 30 mmHg).

Recent studies have highlighted the importance of pulsed Doppler flow analysis in quantifying arteriopathy of the lower limbs, both by systematically analysing flow modulation and by measuring the systolic rise time of distal arteries (dorsal artery of the foot and lateral plantar artery).

The main aim of this study is therefore to validate a reliable and accessible diagnostic tool for screening patients suffering from CLI so that they can be referred to a reference centre as early as possible.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years;
* Patient referred to the vascular medicine department of one of the investigating centres for arterial Doppler ultrasound of at least one lower limb and for whom a measurement of the systolic pressure index at the toe will be performed.
* Presence of proven arterial disease, asymptomatic or not, defined by the presence of one of the following criteria:

  * Rest ankle systolic pressure index ≤ 0.90
  * Rest toe systolic pressure index ≤ 0.70

Exclusion Criteria:

* Patient with haemodynamic instability, unable to tolerate a delay in therapeutic management caused by the ultrasound examination and measurement of systolic pressure at the toe;
* Patients with surgical management of the lower limb (in relation to lower limb arteriopathy), already scheduled at the time of inclusion.
* Patients with a life expectancy of less than 24 hours;
* History of transmetatarsal amputation or amputation at a more proximal level compromising the measurement of systolic pressure and occlusion at the toe and/or TCPO2;
* Refusal to participate
Sequential Analysis in Patients With an Hemopathy

Recent advances in hematology clearly illustrate that the simple "clonal" nature of various hematological malignancies may not really reflect the reality of malignant cells natural expansion. This has been nicely illustrated in recent works in AML for example where subclones coexists in the same patient at the same time, but could also differentially expand over time because of effects of therapeutics intervention, but also by oncogenic spontaneous events (1).

These observations have been done recently because of next generation sequencing that allows to discriminate in the same tumor samples, different subclones and to analyse the clonal architecture. Sequential analyses could help us to identify the first oncogenic event and to correlate disease progression to the emergence of subclones.

For all these reasons it is of a major interest to precisely understand the architecture of the clone in MPNs, especially to understand which is the initiating event and how from this initial event the clone develops.

In MPNs in which JAK2V617F is the initiating event, its targeting is expected to be extremely effective. If JAK2V617F is a secondary event its targeting might allow to alleviate the MPN, but may favor the development of other malignant hemopathies.


Eligibility Criteria:
Inclusion Criteria:

* Patients with a malignant hematological disease.
* Signed written informed consent
* Age and Sex : men and women aged 18 years or older
* Patients affiliated to a social security system

Exclusion Criteria:

- Patients protected by law, in accordance with Articles L1121-L1121-5 to 8 of the Code of Public Health.
Effect of Two Iron Preparations on Protein in the Urine

This pilot study will compare the effects of sodium ferric gluconate complex and iron sucrose on urine concentrations of various chemicals including protein


Eligibility Criteria:
Inclusion Criteria:

* Moderate to severe anemia
* Iron deficiency
* Moderate to severe chronic kidney disease
* Age ≥ 18 or greater and able to give informed consent

Exclusion Criteria:

* Receiving dialysis
* Known sensitivity to Sodium Ferric Gluconate Complex in Sucrose Injection, Iron sucrose USP, or any of their components
* Clinically unstable
* Indication of iron sufficiency
EUS-guided Fine Needle Aspiration (EUS-FNA) Versus EUS-guided Fine Needle Biopsy (EUS-FNB) for Diagnosis of Subepithelial Tumors

Background: Preoperative pathologic diagnosis of subepithelial tumor (SET) can improve clinical decision making. Although EUS-guided fine needle aspiration (FNA) is currently considered the standard method for sampling SET, its diagnostic yield is generally suboptimal. EUS-guided fine needle biopsy (FNB) of SET is safe and feasible with adequate histology obtained.

Objective: To compare the diagnostic accuracy of EUS-FNA and EUS-FNB.


Eligibility Criteria:
Inclusion Criteria:

* Esophageal, gastric, or duodenal SET over 2 cm
* Hypoechoic lesion including 4th layer on EUS

Exclusion Criteria:

* SET with characteristic findings such as lipoma, vessels, or ectopic pancreas
* bleeding or rupture of SET
* platelet count \<50,000 or prothrombin time INR \> 1.3
The Effect of The Musical Toy Used During Peripheral Vascular Access on Children's Pain, Fear And Parents' Satisfaction

The research was carried out as a randomized controlled experimental study in order to examine the effects of the child's pain, fear and parent's satisfaction before and after vascular access with a musical toy-xylophone, which is used as a distraction technique for the preparation of the 3-6 year old child hospitalized in the pediatric clinic.

The population of the study consists of children aged 3-6 years who applied to Durağan Şehit Hakan Tanrıkulu State Hospital Pediatric Service between January 2022 and December 2022 and needed vascular access. The sample of the study consisted of 70 children (control: 35, experiment: 35) who met the case selection criteria. Child and Parent Descriptive Information Form, Child Fear Scale (CFS), Children's Emotional Indicator Scale (CEIS), QUCHER Photographic and Numerical Rating Form (QUCHER), and Nurse-Patient Collaboration Level and Parent Satisfaction Form were used. While the children in the experimental group were playing with a musical toy with their parents, peripheral vascular access was performed.

Eligibility Criteria:
Inclusion Criteria:

* The child is between 3-6 years old,
* Volunteering of parents and children to participate in the research,
* The child does not come to the hospital with acute pain,

Exclusion Criteria:

* The child has a hearing, vision and mental problem,
* The child and the parent do not understand and speak Turkish easily,
* Absence of a primary caregiver,
Vitamin D Level and Its Relation to Pre-eclampsia and Eclampsia

To compare 25(OH)D level in patients with pre-eclampsia, eclampsia and normotensive pregnant women as well as to study the prevalence of Vitamin D deficiency among the 3 groups.

200 patients with pre-eclampsia, 100 with eclampsia and 200 normotensive pregnant controls attending Delivery/emergency department in Kasr Al Ainy hospital will be included in the study (from March 2019 till September 2019). 25(OH) D level will be measured for the three groups.

* Preeclampsia is defined as systolic BP \>140 and/or diastolic BP\>90 on two occasions, 4 hours apart in pregnant females\>20 weeks, plus proteinuria \>/= 1+ urine dipstick protein.
* Eclampsia defined as tonic-clonic seizures in women with pre-eclampsia.
* Controls are normotensive pregnant females with no proteinuria and no other medical disorders.
* The determination of 25(OH) D is based on a competitive enzyme-linked immunosorbant assay (ELISA) using the 25(OH)D3/D2 ELISA system (ORGENTIC DIAGNOSTIKA GmbH, Germany)

Inclusion criteria:

Age 20-35 years Gestational age 30-40 weeks

Exclsion criteria:

Twin pregnancy Other medical conditions during prrgnancy Drugs that influence Vit D levels eg.antiepileptics and antituberculous treatment.

Eligibility Criteria:
Inclusion Criteria:

* Age 20-35 years
* Gestational age 30-40 weeks

Exclusion Criteria:

* Twin pregnancy
* Other medical conditions during pregnancy
* Drugs that influence Vit D levels eg.antiepileptics and antituberculous treatment
Study of Fluoxetine in Patients With Depersonalization Disorder

The purpose of this study is to:

1) Determine the effects of fluoxetine in the treatment of depersonalization disorder, 2) Assess the durability of treatment response in these patients, 3) Assess the improvement in psychiatric disability in these patients, and 4) Assess the effects of comorbid Axis I disorders (depression, social phobia, panic/anxiety, obsessive-compulsive disorder) and Axis II personality disorders on treatment outcome in these patients.

In this trial, participants will be randomly assigned to receive either fluoxetine or placebo. Treatment will consists of two phases (acute treatment and maintenance). In the acute treatment phase, participants will receive fluoxetine or placebo daily for 12 weeks. Participants will be followed every 2 weeks. In the Maintenance phase, participants showing significant improvement after 12 weeks may continue treatment for an additional 6 months. In this phase, participants are followed every 4 weeks.

Participants who do not improve during the acute treatment phase may receive open fluoxetine, or another appropriate medication, for 3 months.

Eligibility Criteria:
Inclusioin Criteria:

* Meets DSM-IV criteria for depersonalization disorder in the last month

Exclusion Criteria:

* Prior or concurrent bio- or chemotherapy or
* Use of any of the following within 2 weeks prior to study entry: antipsychotics, anticonvulsants, stimulants, barbiturates, lithium, benzodiazepines, or antidepressants
* Use of MAO inhibitors or investigational drugs within 4 weeks prior to study entry
* History of fluoxetine use at a dose of 10 mg or more for at least 6 weeks duration
* Hematologic, hepatic, renal, cardiovascular, pulmonary, metabolic, endocrine, systemic, or gastrointestinal disease
* History of mental disorders
* Current substance abuse
* Current eating disorder
* Current clinically unstable suicidal ideation
* Unstable medical illness
* Clinically unstable
* Clinically important abnormalities in lab tests or physical exams
* History of seizure disorders or abnormal electroencephalogram
* Hypersensitivity or severe side effects to fluoxetine
* Pregnancy or breast-feeding. Women of child-bearing potential must use effective contraception
EVALUATION of PREVENTIVE EFFECT of SEALANTS and LASER THERAPY on DENTAL CARIES and POSTERUPTIVE BREAKDOWN on MOLARS AFFECTED with MOLAR INCISOR HYPOMINERALISATION (RANDOMIZED CLINICAL TRIAL)

Background: Molar Incisor Hypomineralisation (MIH) is a qualitative defect of enamel that shows asymmetrical involvement of one to four permanent first molars (PFM) with or without incisor teeth involvement. MIH molars are prone to post-eruptive breakdown (PEB) and to the development of atypical caries lesions.

Aim of the study: To evaluate and compare the preventive effect of glass ionomer sealant and laser therapy (LT) against dental caries and PEB on molars affected by molar incisor hypomineralisation (MIH) Materials and Method: This study is a two-arm, parallel group, randomized clinical trial. A sample of children (n=134) with an age range of 6-9 years old, having a first permanent molar erupted with MIH without PEB or carious lesion, will be selected from the outpatient clinic of Pediatric Dentistry and Public Health Department, Faculty of Dentistry, Alexandria University after securing necessary consents. All selected 134 first permanent molars will be randomly and equally allocated into two groups. Group 1(n=67): LT and Group 2 (n=67): Glass ionomer sealant (Fuji triage). Dental caries, PEB, retention of sealant and child-self-reported discomfort will be clinically evaluated after 6, 12 and 18months. Associations between dental caries and PEB with independent variables will be evaluated using logistic regression analysis (p \< 0.05).


Eligibility Criteria:
Inclusion Criteria:

* 6-9 years old children (29)
* One tooth with MIH with no PEB according to evaluation criteria proposed by Ghanim (2017) (APPENDIX I) (30) and ICDAS scores 0, 1 and 2 (APPENDIX II) (31)
* Good overall health (ASA I) (APPENDIX III) (32)

Exclusion Criteria:

* First permanent molars with active carious lesions with ICDAS scores 5 and 6 (Appendix II) or defective restorations (31)
* Sufficient dentin loss that requires restorative therapy
* Any clinical signs of failure (abscess, fistula)
Prevalence of Toxoplasma Gondii and Toxocara Canis Among Patients With Uveitis

Investigate the prevalence of Toxoplasma gondii and Toxocara canis in Uveitis

* serum antibody to T. gondii and T. canis
* PCR with peripheral blood for T. gondii and T. canis
* PCR with aqueous humor for T. gondii and T. canis
* Clinical manifestation of patient with uveitis

Consecutive patients with uveitis are enrolled in Nune Eye Hospital.

Serum ELISA

* IgM,IgG antibody to Toxoplasma gondii
* IgG antibody to Toxocara canis

PCR

* PCR with serum and aqueous humor to Toxoplasma gondii
* PCR with serum and aqueous humor to Toxocara canis Clinical characteristics
* visual acuity
* intraocular pressure (IOP)
* location and degree of inflammation
* other fundus findings were recorded

questionnaire

* environment, occupation
* pet ownership, exposure to animal
* history of eating raw liver of animal, raw beef or any other raw flesh of animal.

Eligibility Criteria:
Inclusion Criteria:

* patients with uveitis

Exclusion Criteria:

* Patients with history of major ophthalmic surgery within 6 months
* antiviral, antifungal or antiparasitic therapy within 6 months
Development of a Pelvic Cavity Characterization Algorithm Through the Acquisition of MRI Images and Pressure Measurement by an Intravaginal Probe

The conditions such as childbirth or endometriosis can lead to a change in the mobility of the pelvic organs (bladder, vagina, rectum and uterus). The purpose of the study is to study in a personalized way each woman the characteristics of the tissues of their pelvis and to be able to personalize the treatments (surgery, injection, rehabilitation, etc.). Women requiring pelvic MRI may participate in the study. The pelvic dynamic MRI will be done with an intravaginal probe which will be inserted by the patient herself as well as gel in the anus and vagina which will allow to obtain the data on the characteristics of the pelvic tissues of each woman with a 3D reconstruction.


Eligibility Criteria:
Inclusion Criteria:

All:

* Understanding of the French language
* Signature of informed consent
* Insured social patient

For pregnant women:

* Primiparous women
* with no severe maternal-fetal pathology
* with no scheduled caesarean section at the time of the MRI

For women with prolapse:

- Requires pelvic MRI

Exclusion Criteria:

* Minor
* Person who does not have social security
* Person with ongoing vaginal infection
* Pregnant woman during the first or third trimester of pregnancy
* Pregnant woman with broken water pocket
* Bi-cicatricial uterus
* IVF
* Person wearing a pace maker or any intra-body metal implant (if "tube" MRI)
* Claustrophobic person (if "tube" MRI)
China Antiretroviral Treatment Adherence for Life

This study focuses on collecting and analyzing quantitative data related to adherence to antiretroviral treatment from patients in Dali, China, over a one-year time-frame and generating preliminary data on an intervention designed to improve adherence to antiretroviral treatment among the study population.

This study is a continuation of "Adherence for Life (AFL): Phase I: Exploratory Research" (H-25203), which focused on collecting and analyzing qualitative data on adherence to antiretroviral treatment (ART) among HIV-positive patients in Dali, Yunnan Province, China. Like Phase I, the AFL Pilot Study (Phases II and III) will be a collaborative effort between US researchers based in Boston, MA and Chinese researchers based in Beijing and Dali. The current study, Phases II and III, will focus on collecting and analyzing qualitative and quantitative data related to adherence to ART over a one-year time-frame and generating preliminary data on an intervention designed to improve adherence to ART among the study population. The questionnaires used in these phases of the study will draw on the results of Phase I as well as standardized instruments adapted to the Chinese context. The specific aims of the study are as follows: (1) To determine the best surrogate measure of ART adherence among the study population; (2) To determine ART adherence rates in this population; (3) To analyze the relationship between adherence factors and measured adherence rates; and (4) To generate preliminary effectiveness data on an intervention that makes use of electronic drug monitors (EDM) to improve ART adherence.

Eligibility Criteria:
Inclusion Criteria:

* Patients who are 18 years of age or older, currently on antiretroviral treatment or about to begin it, live in the study catchment area, and are willing to provide informed consent.

Exclusion Criteria:

* Persons below the age of 18 years, persons who are not currently on or about to start antiretroviral treatment, persons who live outside the study catchment area, or person not willing to provide informed consent.
MyPADMGT Support of Out-Patients With Peripheral Arterial Disease

The investigators have developed an online program to help people with peripheral arterial disease (PAD) in their extremities to better self-manage their condition. Some earlier testing has been done and the investigators now wish to try this system with participants who have this blood vessel disease as well as high blood pressure. Investigators are hoping to help these participants to achieve healthier lifestyles and improve their quality of life through education, monitoring and continuing support. A similar online desk-top version with over 30 participants has been tested at St. Michael's Hospital in Toronto. The investigators propose to test this newer mobile system with 210 outpatient participants from Hamilton General Hospital. Data collected will be analyzed following the (12 months for each participant) study, along with data recorded during clinical visits at baseline and twelve months for each participant. The objective is to evaluate changes to participant health and determine whether the health self-management process has been successful in improving participant lifestyles and quality of life, when compared to usual care.


Eligibility Criteria:
Inclusion Criteria:

* Out-patients with Peripheral Arterial Disease (Ankle Brachial Index \< 0.90)
* Attending the Hamilton General Hospital Outpatient Vascular Clinic
* May be living alone or with one or more caregivers
* Must have Internet access.

Exclusion Criteria:

* Age \< 18 years
* Not diagnosed with PAD
* Unable to communicate in English
* Unwilling to participate
* Patients with dementia.